The company utilizes third-party manufacturing arrangements on commercially reasonable terms to supply its product candidates, which may require substantial financial capital. These third parties may not consistently adhere to agreed terms and timelines, potentially affecting business plans and commercialization schedules. Long-term manufacturing agreements may contain exclusivity provisions and termination penalties that could negatively impact the company. Reliance on external manufacturers may influence profit margins and the timely commercialization of products. The company may pursue collaborations with biotechnology and pharmaceutical firms for development and commercialization; however, it faces significant competition and challenges in securing such partnerships. Factors affecting these collaborations include clinical trial outcomes, regulatory approval prospects, market potential, manufacturing complexities, competing products, uncertainties regarding technology ownership, and prevailing industry conditions. Recent pharmaceutical business combinations have reduced the pool of potential collaborators, complicating and prolonging negotiations, with risks of delays or failure to establish collaborations, which could result in curtailed development or delayed commercialization.
Verastem Inc's Comment on Supply Chain
The company utilizes third-party manufacturing arrangements on commercially reasonable terms to supply its product candidates, which may require substantial financial capital. These third parties may not consistently adhere to agreed terms and timelines, potentially affecting business plans and commercialization schedules. Long-term manufacturing agreements may contain exclusivity provisions and termination penalties that could negatively impact the company. Reliance on external manufacturers may influence profit margins and the timely commercialization of products. The company may pursue collaborations with biotechnology and pharmaceutical firms for development and commercialization; however, it faces significant competition and challenges in securing such partnerships. Factors affecting these collaborations include clinical trial outcomes, regulatory approval prospects, market potential, manufacturing complexities, competing products, uncertainties regarding technology ownership, and prevailing industry conditions. Recent pharmaceutical business combinations have reduced the pool of potential collaborators, complicating and prolonging negotiations, with risks of delays or failure to establish collaborations, which could result in curtailed development or delayed commercialization.
Sources:
Verastem Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Verastem Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
